Crossmark

Within-subject, double-blinded, randomized, and placebo-controlled evaluation of the combined effects of the cannabinoid dronabinol and the opioid hydromorphone in a human laboratory pain model

Crossref DOI link: https://doi.org/10.1038/s41386-021-01007-4

Published Online: 2021-04-20

Published Print: 2021-07

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Dunn, Kelly E.

Bergeria, Cecilia L.

Huhn, Andrew S.

Speed, Traci J.

Mun, Chung Jung

Vandrey, Ryan

Campbell, Claudia M.
Funding

Funding for this research was provided by:

U.S. Department of Health & Human Services | NIH | National Institute on Drug Abuse (R01DA040644, R01DA042751, R01DA035246)

U.S. Department of Health & Human Services | NIH | National Institute on Drug Abuse

U.S. Department of Health & Human Services | NIH | National Institute on Drug Abuse
License Information

Text and Data Mining valid from 2021-04-20

Version of Record valid from 2021-04-20
More Information

Article History

Received: 29 December 2020

Revised: 4 March 2021

Accepted: 24 March 2021

First Online: 20 April 2021

Document is current

Any future updates will be listed below